Table 1.
Anti-HIV-1 activity of C3 on chronically and acutely HIV-1-infected cellsa
| Cell type | Infection type | TNF-α | EC50b (nM) | CC50c (nM) | SId |
|---|---|---|---|---|---|
| OM-10.1 | Chronic | + | 617 ± 11 | >10,000 | >16 |
| U1 | Chronic | + | 168 ± 97 | >10,000 | >60 |
| CEM | Acute | − | 19.9 ± 3.4 | >1,000 | >50 |
| MOLT-4 | Acute | − | 17.9 ± 6.6 | >1,000 | >55 |
| PBMCs | Acute | − | 9.6 | 6,800 | 708 |
a
All data represent means ± standard deviations for three separate experiments.
b
The EC50 inhibits the level of p24 antigen in culture supernatants by 50%.
c
The CC50 reduces the viability of non-TNF-α-treated OM-10.1 cells and U1 cells or mock-infected CEM cells, MOLT-4 cells, and PBMCs by 50%.
d
The SI is based on the ratio of the CC50 to the EC50.